Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus)
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are to assess the safety, tolerability, pharmacokinetics,
pharmacodynamics and clinical outcome of patients who have severe pneumonia caused by
Staphylococcus aureus (S. aureus) after a single intravenous administration of KBSA301 in
addition of standard of care antibiotic treatment.